NuCyRNA Therapeutics
PrivateLast Round
Grant
Jun 12, 2025
Total Funding Raised
$500,000
Company Overview
NuCyRNA Therapeutics operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Grant round in June 2025.
NuCyRNA Therapeutics is a biotechnology company developing RNA-targeting oligonucleotide therapeutics to address neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NuCyRNA Therapeutics Comparables
Compare NuCyRNA Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Trace Neuroscience | 85% | |
| QurAlis | 76% | |
| Novartis | 68% |
For institutional investors. Book with your work email.
NuCyRNA Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 12, 2025 | ||||
| Seed | Oct 30, 2024 | ||||
| Accelerator | Mar 18, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NuCyRNA Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Harvard Innovation Labs | Accelerator |
| Target ALS | Grant |
| Ono Venture Investment, Inc. | Seed |
| Mission BioCapital | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 12, 2025
Received grant from Target ALS.
- Oct 30, 2024
$500K round led by Mission BioCapital.
For institutional investors. Book with your work email.
NuCyRNA Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NuCyRNA Therapeutics's valuation, stock price, and market status.
Is NuCyRNA Therapeutics a public or private company?
NuCyRNA Therapeutics is a private company.
What is the current stock price of NuCyRNA Therapeutics?
NuCyRNA Therapeutics is a private company, so its shares have no public market price. Caplight tracks NuCyRNA Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NuCyRNA Therapeutics worth (valuation)?
Valuation information for NuCyRNA Therapeutics is not publicly available.
Can I buy NuCyRNA Therapeutics stock?
NuCyRNA Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NuCyRNA Therapeutics's last funding round?
NuCyRNA Therapeutics's most recent funding round was Grant on June 12, 2025.
Who are the main investors in NuCyRNA Therapeutics?
Key investors in NuCyRNA Therapeutics include Mission BioCapital.
Will NuCyRNA Therapeutics IPO soon?
No public IPO plans have been announced for NuCyRNA Therapeutics.
How can I track NuCyRNA Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in NuCyRNA Therapeutics's shares on secondary markets.